Dr. Monzr M. Al Malki
Claim this profileCity of Hope Medical Center
Expert in Acute Myeloid Leukemia
Expert in T-Lymphoblastic Leukemia/Lymphoma
20 reported clinical trials
36 drugs studied
Area of expertise
1Acute Myeloid Leukemia
Global LeaderHLA-A positive
HLA-A negative
HLA positive
2T-Lymphoblastic Leukemia/Lymphoma
Global LeaderHLA-A positive
HLA-A negative
HLA positive
Affiliated Hospitals
Clinical Trials Monzr M. Al Malki is currently running
Extended vs Short-Term Abatacept Dosing
for Graft-versus-Host Disease
This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosing regimen + placebo, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will be compared for their ability to improve outcomes in patients with a minimum follow-up of one year post-transplant. All patients will receive 4 doses of abatacept (Days -1, +5, +14, +28). Prior to the fifth dose, patients will be randomly assigned to the 4-dose abatacept arm and receive 4 doses of placebo or 8-dose abatacept arm and receive 4 more doses of abatacept. The primary endpoint of the study will be severe AGVHD-free, severe CGVHD-free, relapse-free survival (SGRFS). The study will end when the last patient has reached 2 years after transplant. Results will first be calculated and the study unblinded when the last patient has reached one year post-transplant.
Recruiting0 awards Phase 2
Stem Cell Transplantation
for Leukemia
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.
Recruiting1 award Phase 2
More about Monzr M. Al Malki
Clinical Trial Related3 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Monzr M. Al Malki has experience with
- Cyclophosphamide
- Tacrolimus
- Fludarabine
- Melphalan
- Allogeneic Hematopoietic Stem Cell Transplantation
- Mycophenolate Mofetil
Breakdown of trials Monzr M. Al Malki has run
Acute Myeloid Leukemia
T-Lymphoblastic Leukemia/Lymphoma
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Monzr M. Al Malki specialize in?
Monzr M. Al Malki focuses on Acute Myeloid Leukemia and T-Lymphoblastic Leukemia/Lymphoma. In particular, much of their work with Acute Myeloid Leukemia has involved HLA-A positive patients, or patients who are HLA-A negative.
Is Monzr M. Al Malki currently recruiting for clinical trials?
Yes, Monzr M. Al Malki is currently recruiting for 10 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Monzr M. Al Malki has studied deeply?
Yes, Monzr M. Al Malki has studied treatments such as Cyclophosphamide, Tacrolimus, Fludarabine.
What is the best way to schedule an appointment with Monzr M. Al Malki?
Apply for one of the trials that Monzr M. Al Malki is conducting.
What is the office address of Monzr M. Al Malki?
The office of Monzr M. Al Malki is located at: City of Hope Medical Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.